FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroGen in a report on Thursday.

FibroGen Stock Performance

FibroGen stock opened at $0.71 on Friday. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The firm’s 50-day moving average is $0.52 and its 200-day moving average is $0.43. The company has a market cap of $71.13 million, a P/E ratio of -0.57 and a beta of 0.75.

Hedge Funds Weigh In On FibroGen

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 1,358,194 shares during the period. FMR LLC boosted its holdings in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the period. Franklin Street Advisors Inc. NC boosted its holdings in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 100,000 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of FibroGen during the third quarter valued at $307,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.